Venous thromboembolic events Duration of hospital stay (whole population) · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Reduction in pain · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Triamcinolone acetonide 0.1% ointment (topical) led to higher positive response (not defined) compared with phenytoin syrup mouthwash (30 mg in 5 mL); GRADE not reported.
1 finding from 1 review
Plaque · Adults with dental implants and peri-implant mucositis at baseline
Mechanical debridement plus topical minocycline showed no clear difference in plaque compared with mechanical debridement plus chlorhexidine gel; GRADE not reported.
1 finding from 1 review
Change in probing pocket depth (PPD) · Adults with dental implants and peri-implant mucositis at baseline
Mechanical debridement plus topical minocycline showed no clear difference in change in probing pocket depth compared with mechanical debridement plus chlorhexidine gel; GRADE not reported.
1 finding from 1 review
Change in probing pocket depth (worst sites) · Adults with dental implants and peri-implant mucositis at baseline
Mechanical debridement plus topical minocycline showed no clear difference in change in probing pocket depth (worst sites) compared with mechanical debridement plus chlorhexidine gel; GRADE not reported.
1 finding from 1 review
Soreness in the gums · Adults with dental implants and peri-implant mucositis at baseline
Mechanical debridement plus topical minocycline showed no clear difference in soreness in the gums compared with mechanical debridement plus chlorhexidine gel; GRADE not reported.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
MD -51.02 [-72.85, -29.20]
2 studies · 85 participants
Very low
MD -38.79 [-52.06, -25.53]
2 studies · 85 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
HRQOL RosaQoL · Participants with rosacea
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Clindamycin phosphate 1.2% + tretinoin 0.025% gel probably leads to higher proportion of participants with adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
Clindamycin phosphate 1.2% + tretinoin 0.025% gel showed no clear difference in assessment of erythema or telangiectasia compared with placebo (moderate certainty).
1 finding from 1 review